Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

prostaglandin E2 EP4 receptor inhibitor AN0025

An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, AN0025 selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	EP4 antagonist E7046 EP4 inhibitor E7046 prostaglandin E EP4 receptor antagonist E7046
Code name:	AN 0025 AN0025 E 7046 E7046

prostaglandin E2 EP4 receptor inhibitor AN0025

Search NCI's Drug Dictionary